PRPO - Precipio, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Precipio, Inc.

4 Science Park
New Haven, CT 06511
United States

IndustryDiagnostics & Research
Full Time Employees42

Key Executives

NameTitlePayExercisedYear Born
Mr. Ilan DanieliFounder, Pres, CEO & Director263.8kN/A1972
Mr. Carl R. IbergerCFO & Sec.208.16kN/A1953
Mr. Ahmed Zaki SabetChief Operating Officer163.69kN/A1986
Mr. Douglas SitesVP of SalesN/AN/AN/A
Mr. Ayman MohamedSr. VP of R&D and Laboratory OperationsN/AN/A1985
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Precipio, Inc., a cancer diagnostics company, provides diagnostic products and services to the oncology market. It also develops a platform to eradicate the problem of misdiagnosis within academic institutions. In addition, the company delivers diagnostic information to physicians and their patients worldwide. It has partnership agreements with the Yale School of Medicine, Dana-Farber Cancer Institute, Inc. and other institutions specializing in cancer research, diagnostics, and treatment; and development agreement with H3 Biomedicine to create a targeted gene panel. The company is based in New Haven, Connecticut.

Corporate Governance

Precipio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.